Maternal genotype and severe preeclampsia: A HuGE review

American Journal of Epidemiology

Volumn 180, Issue 4, 2014, Pages 335-345

  Fong, Fiona M ^a   Sahemey, Manpreet K ^a   Hamedi, Golnessa ^a   Eyitayo, Rachel ^a   Yates, Derick ^b   Kuan, Valerie ^a   Thangaratinam, Shakila ^a,c   Walton, Robert T ^a,c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Complications; Epidemiology; F5 gene; Factor V Leiden; Genetics; Meta analysis; Severe preeclampsia; Systematic review; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5; LEPTIN RECEPTOR; PROTHROMBIN;

BLOOD SYSTEM DISORDER; DISEASE SEVERITY; EPIDEMIOLOGY; GENOTYPE; HEALTH RISK; LITERATURE REVIEW; MATERNAL HEALTH; META-ANALYSIS; MORBIDITY;

CASE CONTROL STUDY; COHORT ANALYSIS; DATA EXTRACTION; EMBASE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MEDLINE; PREECLAMPSIA; PROSPECTIVE STUDY; QUALITY CONTROL; RETROSPECTIVE STUDY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; FEMALE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; META ANALYSIS; PREGNANCY; RISK FACTOR; THROMBOPHILIA;

FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS; THROMBOPHILIA;

EID: 84907378570     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu151     Document Type: Review

References (110)

1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3): 130-137.
2. Khan KS,Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367(9516): 1066-1074.
3. Steegers EA, von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. Lancet. 2010;376(9741): 631-644.
4. World Health Organization. The World Health Report 2005: Make Every Mother and Child Count. http://www.who.int/whr/2005/whr2005-en.pdf. Accessed December 16, 2013.
5. Sibai BM, Barton JR. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol. 2007;196(6): 514.e1-514.e9.
6. Roberge S, Nicolaides KH, Demers S, et al. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-Analysis. Ultrasound Obstet Gynecol. 2013; 41(5): 491-499.
7. Thangaratinam S, Ismail K, Sharp S, et al. Prioritisation of tests for the prediction of preeclampsia complications: a Delphi survey. Hypertens Pregnancy. 2007;26(1): 131-138.
8. Thangaratinam S, Coomarasamy A, O'Mahony F, et al. Estimation of proteinuria as a predictor of complications of pre-eclampsia: a systematic review. BMC Med. 2009;7: 10.
9. Thangaratinam S, Gallos ID, Meah N, et al. How accurate are maternal symptoms in predicting impending complications in women with preeclampsia? A systematic review and meta-Analysis. Acta Obstet Gynecol Scand. 2011;90(6): 564-573.
10. Thangaratinam S, Koopmans CM, Iyengar S, et al. Accuracy of liver function tests for predicting adverse maternal and fetal outcomes in women with preeclampsia: a systematic review. Acta Obstet Gynecol Scand. 2011;90(6): 574-585.
11. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330(7491): 565.
12. Seremak-Mrzoikiewicz A. Genetics of preeclampsia-current concepts. Arch Perinat Med. 2008;14(4): 9-11.
13. Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. Br J Obstet Gynaecol. 1992;99(7): 547-553.
14. Lin J, August P. Genetic thrombophilias and preeclampsia: a meta-Analysis. Obstet Gynecol. 2005;105(1): 182-192.
15. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132(2): 171-196.
16. Staines-Urias E, Paez MC, Doyle P, et al. Genetic association studies in pre-eclampsia: systematic meta-Analyses and field synopsis. Int J Epidemiol. 2012;41(6): 1764-1775.
17. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol. 2002;101(1): 6-14.
18. Rodger MA, Betancourt MT, Clark P, et al. The association of factor V Leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-Analysis of prospective cohort studies. PLoS Med. 2010;7(6): e1000292.
19. Little J, Higgins J. eds. The HuGENet HuGE Review Handbook, version 1.0. http://www.med.uottawa.ca/publichealth-genomics/web/assets/documents/ HuGE-Review-Handbook-V1-0.pdf. Accessed February 28, 2013.
20. Fong F, Sahemey M, Thangaratinam S, et al. Genetic Association with Maternal and Fetal Adverse Outcomes in pre-Eclampsia: A Systematic Review and Meta-Analysis. PROSPERO: international prospective register of systematic reviews; 2012; CRD42012003052.
21. NICE. Hypertension in Pregnancy. The Management of Hypertensive Disorders During Pregnancy. (NICE Clinical Guideline 107). London, United Kingdom: National Institute for Health and Care Excellence; 2011.
22. Tranquilli AL, Brown MA, Zeeman GG, et al. The definition of severe and early onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Pregnancy Hypertens. 2013;14: 44-47.
23. Yu W, Gwinn M, Clyne M, et al. A navigator for human genome epidemiology. Nat Genet. 2008;40(2): 124-125.
24. Little J, Higgins J, Ioannidis J, et al. STrengthening the REporting of Genetic Association studies (STREGA): an extension of the STROBE statement. PLoS Med. 2009;6(2): e1000022.
25. Wilson A, Lissauer D, Thangaratinam S, et al. A comparison of clinical officers with medical doctors on outcomes of caesarean section in the developing world: meta-Analysis of controlled studies. BMJ. 2011;342: d2600.
26. Wells G. The Newcastle Ottawa Scale (NOS) for Assessing the Quality of Non-Randomised Studies in Meta-Analysis. Oxford, United Kingdom: Oxford; 2000.
27. Hosking L, Lumsden S, Lewis K, et al. Detection of genotyping errors by Hardy-Weinberg equilibrium testing. Eur J Hum Genet. 2004;12(5): 395-399.
28. Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008;37(1): 120-132.
29. Khoury MJ, Bertram L, Boffetta P, et al. Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol. 2009;170(3): 269-279.
30. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-Analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20): 3443-3457.
31. Review Manager (RevMan) computer program. Version 5.2. Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration; 2012.
32. Stata Corporation. Stata statistical software, release 12. College Station, TX: Stata Corporation; 2013.
33. Wang XL, Wang Q, Sun CJ, et al. Genetic polymorphisms of killer cell immunoglobulin-like receptor 3DL2 in preeclampsia. J Perinat Med. 2011;39(3): 273-278.
34. Wiedemann A, Vocke F, Fitzgerald JS, et al. Leptin gene (TTTC)(n) microsatellite polymorphism as well as leptin receptor R223Q and PPARgamma2 P12A substitutions are not associated with hypertensive disorders in pregnancy. Am J Reprod Immunol. 2010;63(4): 310-317.
35. Zhu H, Zhao YH, Zhang WY, et al. Relationship between dopamine-beta-hydroxylase gene polymorphism and hypertensive disorder complicating pregnancy [in Chinese]. Zhonghua Fu Chan Ke Za Zhi. 2006;41(6): 384-386.
36. Youpeng B, Wei X, Wei L, et al. Relationships among adiponectin gene polymorphisms, proteinuria and increased blood pressure in the context of placental diseases. Hypertens Res. 2010;33(10): 1066-1070.
37. Gerhardt A, GoeckeTW, BeckmannMW, et al. The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia. J Thromb Haemost. 2005;3(4): 686-691.
38. Currie L, Peek M, McNiven M, et al. Is there an increased maternal-infant prevalence of factor V Leiden in association with severe pre-eclampsia? BJOG. 2002;109(2): 191-196.
39. Deveer R, Engin-Ustun Y, Akbaba E, et al. Association between pre-eclampsia and inherited thrombophilias. Fetal Pediatr Pathol. 2013;32(3): 213-217.
40. Dizon-Townson DS, Nelson LM, Easton K, et al. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol. 1996;175(4 Pt 1): 902-905.
41. Kim SY, Lim JH, Park SY, et al. Transforming growth factor-beta 1 gene polymorphisms in Korean patients with pre-eclampsia. Am J Reprod Immunol. 2010;63(4): 291-298.
42. Livingston JC, Barton JR, Park V, et al. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol. 2001;185(1): 153-157.
43. Hiltunen LM, Laivuori H, Rautanen A, et al. Blood group AB and factor V Leiden as risk factors for pre-eclampsia: a population-based nested case-control study. Thromb Res. 2009;124(2): 167-173.
44. Sziller I, Babula O, Hupuczi P, et al. Mannose-binding lectin (MBL) codon 54 gene polymorphism protects against development of pre-eclampsia, HELLP syndrome and pre-eclampsia-Associated intrauterine growth restriction. Mol Hum Reprod. 2007;13(4): 281-285.
45. Várkonyi T, Lázár L, Molvarec A, et al. Leptin receptor (LEPR) SNP polymorphisms in HELLP syndrome patients determined by quantitative real-Time PCR and melting curve analysis. BMC Med Genet. 2010;11: 25.
46. De Groot CJ, Bloemenkamp KW, Duvekot EJ, et al. Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol. 1999;181(4): 975-980.
47. Derzbach L, Balogh A, Bokodi G, et al. Ser128Arg E-selectin and Thr715Pro P-selectin polymorphisms and severe preeclampsia. J Reprod Med. 2007;52(9): 815-818.
48. Molvarec A, Vér A, Fekete A, et al. Association between estrogen receptor alpha (ESR1) gene polymorphisms and severe preeclampsia. Hypertens Res. 2007;30(3): 205-211.
49. Molvarec A, Jermendy A, Nagy B, et al. Association between tumor necrosis factor (TNF)-Alpha G-308A gene polymorphism and preeclampsia complicated by severe fetal growth restriction. Clin Chim Acta. 2008;392(1-2): 52-57.
50. Rosta K, Molvarec A, Enzsöly A, et al. Association of extracellular superoxide dismutase (SOD3) Ala40Thr gene polymorphism with pre-eclampsia complicated by severe fetal growth restriction. Eur J Obstet Gynecol Reprod Biol. 2009; 142(2): 134-138.
51. Alfirevic Z, Mousa HA, Martlew V, et al. Postnatal screening for thrombophilia in women with severe pregnancy complications. Obstet Gynecol. 2001;97(5 Pt 1): 753-759.
52. Pendeloski KP, Sass N, Torloni MR, et al. Immunoregulatory gene polymorphisms in women with preeclampsia. Hypertens Res. 2011;34(3): 384-388.
53. Aggarwal S, Dimri N, Tandon I, et al. Preeclampsia in North Indian women: the contribution of genetic polymorphisms. J Obstet Gynaecol Res. 2011;37(10): 1335-1341.
54. Kaur R, Jain V, Khuller M, et al. Association of angiotensin-converting enzyme gene polymorphism with pregnancy-induced hypertension. Acta Obstet Gynecol Scand. 2005;84(10): 929-933.
55. Mandô C, Antonazzo P, Tabano S, et al. Angiotensin-converting enzyme and adducin-1 polymorphisms in women with preeclampsia and gestational hypertension. Reprod Sci. 2009;16(9): 819-826.
56. Roberts CB, Rom L, Moodley J, et al. Hypertension-related gene polymorphisms in pre-eclampsia, eclampsia and gestational hypertension in black South African women. J Hypertens. 2004;22(5): 945-948.
57. Procopciuc L, Jebeleanu G, Surcel I, et al. Angiotensinogen gene M235T variant and pre-eclampsia in Romanian pregnant women. J Cell Mol Med. 2002;6(3): 383-388.
58. Tempfer CB, Jirecek S, Riener EK, et al. Polymorphisms of thrombophilic and vasoactive genes and severe preeclampsia: a pilot study. J Soc Gynecol Investig. 2004;11(4): 227-231.
59. Agorastos T, Karavida A, Lambropoulos A, et al. Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome. J Matern Fetal Neonatal Med. 2002; 12(4): 267-273.
60. Benedetto C, Marozio L, Salton L, et al. Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome. Acta Obstet Gynecol Scand. 2002;81(12): 1095-1100.
61. Kim Y, Williamson R, Murray J, et al. Genetic susceptibility to preeclampsia: roles of cytosine-To-Thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-base pair insertion at nucleotide 844 of the gene for cystathionine beta-synthase, and factor V Leiden mutation. Am J Obstet Gynecol. 2001;184(6): 1211-1217.
62. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340(1): 9-13.
63. Kupferminc MJ, Fait G, Many A, et al. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol. 2000;96(1): 45-49.
64. Malek-Khosravi S, Rahimi Z, Rahimi Z, et al. Thrombophilic mutations and susceptibility to preeclampsia in Western Iran. J Thromb Thrombolysis. 2012;33(1): 109-115.
65. Muetze S, Leeners B, Ortlepp JR, et al. Maternal factor V Leiden mutation is associated with HELLP syndrome in Caucasian women. Acta Obstet Gynecol Scand. 2008;87(6): 635-642.
66. Nagy B, Tóth T, Rigó J Jr, et al. Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women. Clin Genet. 1998;53(6): 478-481.
67. Rigó J Jr, Nagy B, Fintor L, et al. Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase. Hypertens Pregnancy. 2000;19(2): 163-172.
68. Schlembach D, Beinder E, Zingsem J, et al. Association of maternal and/or fetal factor V Leiden and G20210A prothrombin mutation with HELLP syndrome and intrauterine growth restriction. Clin Sci (Lond). 2003;105(3): 279-285.
69. Seremak-Mrozikiewicz A, Drews K, Wender-Ozegowska E, et al. The significance of genetic polymorphisms of factor V Leiden and prothrombin in the preeclamptic Polish women. J Thromb Thrombolysis. 2010;30(1): 97-104.
70. van Pampus MG, Wolf H, Koopman MM, et al. Prothrombin 20210 G: a mutation and factor V Leiden mutation in women with a history of severe preeclampsia and (H)ELLP syndrome. Hypertens Pregnancy. 2001;20(3): 291-298.
71. von Tempelhoff GF, Heilmann L, Spanuth E, et al. Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-Antibodies in patients with preeclampsia or HELLP-syndrome. Hemolysis, elevated liver-enzymes, low platelets. Thromb Res. 2000; 100(4): 363-365.
72. Nagy B, Varkonyi T, Molvarec A, et al. Leptin gene (TTTC)(n) microsatellite polymorphism in pre-eclampsia and HELLP syndrome. Clin Chem Lab Med. 2009;47(9): 1033-1037.
73. Rigó J, Szendei G, Rosta K, et al. Leptin receptor gene polymorphisms in severely pre-eclamptic women. Gynecol Endocrinol. 2006;22(9): 521-525.
74. Guan LX, Gao L, Gao Y, et al. Association of leptin level and leptin receptor gene polymorphisms with susceptibility to severe pre-eclampsia [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2011;28(5): 562-567.
75. Kobashi G, Yamada H, Asano T, et al. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and preeclampsia in Japanese women. Am J Med Genet. 2000;93(2): 122-125.
76. de Lima TH, Sass N, Mattar R, et al. Cytokine gene polymorphisms in preeclampsia and eclampsia. Hypertens Res. 2009;32(7): 565-569.
77. Kaiser T, Grehan M, Brennecke S, et al. Association of the TNF2 allele with eclampsia. Gynecol Obstet Invest. 2004; 57(4): 204-209.
78. Pazarbasi A, Kasap M, Güzel AI, et al. Polymorphisms in the tumor necrosis factor-Alpha gene in Turkish women with pre-eclampsia and eclampsia. Acta Med Okayama. 2007; 61(3): 153-160.
79. James D, Steer P, Weiner C, et al. High Risk Pregnancy: Management Options. 4th ed. Edinburgh, United Kingdom: Saunders/Elsevier; 2011.
80. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009;30(suppl A): S32-S37.
81. Casciola-Rosen L, Rosen A, Petri M, et al. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci U S A. 1996;93(4): 1624-1629.
82. Said J, Dekker G. Pre-eclampsia and thrombophilia. Best Pract Res Clin Obstet Gynaecol. 2003;17(3): 441-458.
83. Anim-Nyame N, Sooranna SR, Steer PJ, et al. Longitudinal analysis of maternal plasma leptin concentrations during normal pregnancy and pre-eclampsia. Hum Reprod. 2000; 15(9): 2033-2036.
84. Molvarec A, Szarka A,Walentin S, et al. Serum leptin levels in relation to circulating cytokines, chemokines, adhesion molecules and angiogenic factors in normal pregnancy and preeclampsia. Reprod Biol Endocrinol. 2011;9: 124.
85. Poston L. Leptin and preeclampsia. Semin Reprod Med. 2002; 20(2): 131-138.
86. Eikelis N, Schlaich M, Aggarwal A, et al. Interactions between leptin and the human sympathetic nervous system. Hypertension. 2003;41(5): 1072-1079.
87. Arngrímsson R, Sigurõardóttir S, Frigge ML, et al. A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. Hum Mol Genet. 1999; 8(9): 1799-1805.
88. Harrison GA, Humphrey KE, Jones N, et al. A genomewide linkage study of preeclampsia/eclampsia reveals evidence for a candidate region on 4q. Am J Hum Genet. 1997;60(5): 1158-1167.
89. Lachmeijer AM, Arngrímsson R, Bastiaans EJ, et al. A genome-wide scan for preeclampsia in the Netherlands. Eur J Hum Genet. 2001;9(10): 758-764.
90. Laivuori H, Lahermo P, Ollikainen V, et al. Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet. 2003;72(1): 168-177.
91. Moses E, Lade J, Guo G, et al. A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am J Hum Genet. 2000;67(6): 1581-1585.
92. Johnson MP, Brennecke SP, East CE, et al. Genome-wide association scan identifies a risk locus for preeclampsia on 2q14, near the inhibin, beta B gene. PLoS One. 2012;7(3): e33666.
93. Zhao L, Triche EW, Walsh KM, et al. Genome-wide association study identifies a maternal copy-number deletion in PSG11 enriched among preeclampsia patients. BMC Pregnancy Childbirth. 2012;12: 61.
94. Caniggia I, Winter J, Lye SJ, et al. Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia. Placenta. 2000;21(suppl A): S25-S30.
95. Casagrandi D, Bearfield C, Geary J, et al. Inhibin, activin, follistatin, activin receptors and beta-glycan gene expression in the placental tissue of patients with pre-eclampsia. Mol Hum Reprod. 2003;9(4): 199-203.
96. Fraser RF 2nd, McAsey ME, Coney P. Inhibin-A and pro-Alpha C are elevated in preeclamptic pregnancy and correlate with human chorionic gonadotropin. Am J Reprod Immunol. 1998;40(1): 37-42.
97. Muttukrishna S, Knight PG, Groome NP, et al. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet. 1997;349(9061): 1285-1288.
98. Muttukrishna S, North RA, Morris J, et al. Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia. Hum Reprod. 2000;15(7): 1640-1645.
99. Petraglia F, Aguzzoli L, Gallinelli A, et al. Hypertension in pregnancy: changes in activin A maternal serum concentration. Placenta. 1995;16(5): 447-454.
100. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6): 642-649.
101. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda). 2009;24: 147-158.
102. Andraweera PH, Dekker GA, Thompson SD, et al. A functional variant in ANGPT1 and the risk of pregnancies with hypertensive disorders and small-for-gestational-Age infants. Mol Hum Reprod. 2012;18(6): 325-332.
103. Kvehaugen AS, Melien O, Holmen OL, et al. Single nucleotide polymorphisms in G protein signaling pathway genes in preeclampsia. Hypertension. 2013;61(3): 655-661.
104. Percin FE, Cetin M, Pinarbasi E, et al. Lack of association between the CYP11B2 gene polymorphism and preeclampsia, eclampsia, and the HELLP syndrome in Turkish women. Eur J Obstet Gynecol Reprod Biol. 2006; 127(2): 213-217.
105. Ahmadi R, Rahimi Z, Vaisi-Raygani A, et al. Apolipoprotein E genotypes, lipid peroxidation, and antioxidant status among mild and severe preeclamptic women from western Iran: protective role of apolipoprotein e2 allele in severe preeclampsia. Hypertens Pregnancy. 2012;31(4): 405-418.
106. Lim JH, Kim SY, Kim do J, et al. Genetic polymorphism of catechol-O-methyltransferase and cytochrome P450c17a in preeclampsia. Pharmacogenet Genomics. 2010;20(10): 605-610.
107. Procopciuc LM, Hazi GM, Caracostea G, et al. The effect of the D1-C785T polymorphism in the type 1 iodothyronine deiodinase gene on the circulating thyroid hormone levels in Romanian women with preeclampsia. Association with the degree of severity and pregnancy outcome of preeclampsia. Gynecol Endocrinol. 2012;28(5): 386-390.
108. Kwon HS, Sohn IS, Hwang HS, et al. Intercellular adhesion molecule-1 K469E polymorphism: Is it associated with preeclampsia in the Korean population? J Reprod Med. 2012; 57(3-4): 148-152.
109. Stepanian A, Benchenni S, Beillat-Lucas T, et al. Search for an association between V249I and T280M CX3CR1 genetic polymorphisms, endothelial injury and preeclampsia: the ECLAXIR Study. PLoS One. 2009;4(7): e6192.
110. Raijmakers MT, Roes EM., Steegers EA, et al. The C242T-polymorphism of the NADPH/NADH oxidase gene p22phox subunit is not associated with pre-eclampsia. J Hum Hypertens. 2002;16(6): 423-425.